Seurat Therapeutics is focused on developing innovative treatments for neurological disorders, particularly targeting conditions such as migraines, fibromyalgia, and seizure disorders. One of the key technologies the company is exploring involves the use of Insulin-like Growth Factor 1 (IGF-1) for migraine relief. Research indicates that IGF-1 can significantly reduce susceptibility to cortical spreading depression, a phenomenon linked to migraine aura and pain. The protective effects of IGF-1 are achieved through its ability to inhibit hyperexcitability in the brain, reduce inflammation, and lower the production of free radicals. This has been demonstrated in both cultured rodent brain slices and through nasal delivery methods, which have shown promising results in mitigating migraine-related pain.

The nasal delivery of IGF-1 has been shown to effectively inhibit the activation of the trigeminal system, which is crucial in the development of migraine pain. Studies reveal that this method not only reduces oxidative stress in the trigeminal ganglion but also lowers levels of calcitonin gene-related peptide (CGRP), a key mediator of migraine pain. Furthermore, the protective effects of nasal IGF-1 have been observed even after the administration of nitroglycerin, a known migraine trigger. Overall, Seurat Therapeutics is pioneering a novel approach to pain relief by leveraging the neuroprotective properties of IGF-1, aiming to transform the treatment landscape for patients suffering from debilitating neurological conditions.

United States

Seurat Therapeutics is focused on developing medication to safely and effectively treat and prevent migraines.

Seurat Therapeutics

Company Details